NewAmsterdam Pharma (NASDAQ:NAMS) Stock Quotes, Forecast and News Summary

Q: What sector and industry does NewAmsterdam Pharma (NAMS) operate in?

NewAmsterdam Pharma is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

NewAmsterdam Pharma Stock (NASDAQ: NAMS) stock price, news, charts, stock research, profile.

Open	$20.12
Close	$19.59
Volume / Avg.	95.45K / 182.68K
Day Range	19.41 - 20.45
52 Wk Range	5.63 - 26.35
Market Cap	$1.78B
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	48
Short Interest	0.42%
Days to Cover	1.09

Recent News

Why TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCode Therapeutics priced a 5,942,623 share common stock offering at $1.22 per share. TransCode Therapeutics shares dipped 24.3% to $0.8248 on Friday.

Avi Kapoor

World Acceptance Posts Upbeat Earnings, Joins Kaman, Spirit Airlines And Other Big Stocks Moving Higher On Friday

U.S. stocks traded higher, with the Dow Jones index gaining around 50 points on Friday. Shares of World Acceptance Corporation (NASDAQ: WRLD) rose sharply during Friday’s session following upbeat quarterly results.

Avi Kapoor

Cholesterol Player NewAmsterdam Pharma's Obicetrapib Is A Potential Blockbuster In Cardiovascular Market: Bullish Analyst Says

Piper Sandler's coverage on NewAmsterdam Pharma and its clinical-stage therapy, Obicetrapib, a potent CETP inhibitor targeting cardiovascular health. With a unique mechanism, superior efficacy, and market potential, Piper gives an Overweight rating and a $37 price target.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trends and Forecast

Jan

Feb

Mar

May

Jun

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.8

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

About NewAmsterdam Pharma Company NV

Sector

Health Care

Industry

Biotechnology

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patien...

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy NewAmsterdam Pharma (NAMS) stock?

You can purchase shares of NewAmsterdam Pharma (NASDAQ:NAMS) through any online brokerage.

View our list of the best stock brokerages

Who are NewAmsterdam Pharma (NAMS) competitors?

Other companies in NewAmsterdam Pharma’s space includes: 4D Molecular Therapeutics (NASDAQ:FDMT), Syndax Pharmaceuticals (NASDAQ:SNDX), Protagonist Therapeutics (NASDAQ:PTGX), Kiniksa Pharmaceuticals (NASDAQ:KNSA) and Bicycle Therapeutics (NASDAQ:BCYC).

What is the target price for NewAmsterdam Pharma (NAMS) stock?

There is no analysis for NewAmsterdam Pharma.

What is the forecast for NewAmsterdam Pharma (NAMS) stock?

NewAmsterdam Pharma has a consensus price target of $28.29.

Current stock price for NewAmsterdam Pharma (NAMS)?

The stock price for NewAmsterdam Pharma (NASDAQ: NAMS) is $19.78 last updated July 15, 2024 at 4:13 PM EDT.

Does NewAmsterdam Pharma (NAMS) pay a dividend?

There are no upcoming dividends for NewAmsterdam Pharma.

When is NewAmsterdam Pharma (NASDAQ:NAMS) reporting earnings?

NewAmsterdam Pharma does not have any upcoming earnings scheduled.

Is NewAmsterdam Pharma (NAMS) going to split?

There is no upcoming split for NewAmsterdam Pharma.

What sector and industry does NewAmsterdam Pharma (NAMS) operate in?

NewAmsterdam Pharma is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

NewAmsterdam Pharma

NewAmsterdam Pharma (NAMS) Forecast